참고문헌
- Arica B, Calis S, Kas H, S, et al (2002). 5-Fluorouracil encapsulated alginate beads for the treatment of breast cancer. Int J Pharm, 242, 267-69. https://doi.org/10.1016/S0378-5173(02)00172-2
- Batliwalla, Bateman, Serrano, et al (1998 ). A 15-year followup of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med, 4, 783-94.
- Bentires-Alj M, Hellin AC, Lechanteur C, et al (2000). Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther, 7, 20-26. https://doi.org/10.1038/sj.cgt.7700093
- Bentires-Alj M, Hellin AC, Lechanteur C, et al (2000). Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther, 7, 20-26. https://doi.org/10.1038/sj.cgt.7700093
- Cassel WA, Murray DR (1988). Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul, 7, 351-52.
- Dachs GU, Hunt MA, Syddall S, et al (2009). Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules, 14, 4517-45. https://doi.org/10.3390/molecules14114517
- Fabian Z, Csatary CM, Szeberenyi J, et al (2007). p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol, 81, 2817-30. https://doi.org/10.1128/JVI.02490-06
- Frederick MA (2002) (ed). Current Protocols in Molecular Biology, New York, John Wiley & Sons.
- Fuchita M, Ardiani A, Zhao L, et al (2009). Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res, 69, 4791-99. https://doi.org/10.1158/0008-5472.CAN-09-0615
- Huber BE, Austin EA, Richards CA, et al (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA, 9, 18302-6.
- Ichikawa T, Tamiya T, Adachi Y, et al (2000). In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther, 7, 74-82. https://doi.org/10.1038/sj.cgt.7700086
- Kaliberova LN, Manna DLD, Krendelchtchikova V, et al (2008). Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther, 7, 2845-54. https://doi.org/10.1158/1535-7163.MCT-08-0347
- Karcher J, Dyckhoff G, Beckhove P, et al (2004). Anti-tumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res, 64, 8057-61. https://doi.org/10.1158/0008-5472.CAN-04-1545
- Khatri A, Zhang B, Doherty E, et al (2006). Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med, 8, 1086-96. https://doi.org/10.1002/jgm.944
- Knipe DM, Howley PM, Griffin DE, et al (2006). Fields virology. 5th ed, Philly, Lippincott Williams & Wilkins.
- Liang W, Wang H, Sun TM, et al (2003). Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol, 9, 495-98. https://doi.org/10.3748/wjg.v9.i3.495
- Nakaya T, Cros J, Park MS, et al (2001). Recombinant Newcastle disease virus as a vaccine vector. J Virol, 75, 11868-73. https://doi.org/10.1128/JVI.75.23.11868-11873.2001
-
Negroni L, Samson M, Guigonis J, et al (2007). Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome and
$Hsp90\beta$ phosphorylation. Mol Cancer Ther, 6, 2747-56. https://doi.org/10.1158/1535-7163.MCT-07-0040 - Ockert D, Schirrmacher V, Beck N, et al (1996). Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res, 2, 21-28.
- Patyar S, Joshi R, Byrav DSP, et al (2010). Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci, 17, 21-29. https://doi.org/10.1186/1423-0127-17-21
- Peeters BP, Leeuw OS, Koch G, et al (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol, 73, 5001-9.
- Pierrefite-Carle V, Baque P, Gavelli A, et al (1999). Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst, 91, 2014-19. https://doi.org/10.1093/jnci/91.23.2014
- Ravindra PV, Tiwari AK, Romer-Oberdorfer A, et al (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol, 80, 2987-95. https://doi.org/10.1099/0022-1317-80-11-2987
- Schirrmacher V, Haas C, Bonifer R, et al (1999). Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther, 6, 63-73. https://doi.org/10.1038/sj.gt.3300787
- Schlag P, Manasterski M, Gerneth T, et al (1992). Active specific immunotherapy with Newcastle-disease-virusmodified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol Immunothe, 35, 325-30. https://doi.org/10.1007/BF01741145
- Schneider T, Gerhards R, Kirches E, Firsching R (2001). Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol, 53, 39-46. https://doi.org/10.1023/A:1011856406683
- Springer CJ (2004). Suicide Gene Therapy, Methods and Reviews, (Totowa) New Jersey.
- Springer CJ, Niculescu-Duvaz I (1996). Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv Drug Deliv Rev, 22, 351-64. https://doi.org/10.1016/S0169-409X(96)00449-8
- Steiner HH, Bonsanto MM, Beckhove P, et al (2004). Anti-tumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol, 22, 4272-81. https://doi.org/10.1200/JCO.2004.09.038
- Stolworty TS, Aaron MK, Candice LW, et al (2008). Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J Mol Biol, 377, 854-69. https://doi.org/10.1016/j.jmb.2008.01.002
- Topf N, Worgall S, Hackett NR, Crystal RG (1998). Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther, 5, 507-13. https://doi.org/10.1038/sj.gt.3300611
- Toshiaki T, Duflot-Dance A, Tiraby M, et al (2009). Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions. Cancer Lett, 282, 43-47. https://doi.org/10.1016/j.canlet.2009.02.050
- Vigil A, Martinez O, Chua MA, Garcia-Sastre A (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther, 16, 1883-90. https://doi.org/10.1038/mt.2008.181
- Wallack MK, Sivanandham M, Balch CM, et al (1998). Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg, 187, 69-77. https://doi.org/10.1016/S1072-7515(98)00097-0
- Zamarin D, Martinez-Sobrido L, Kelly K, et al (2009). Enhancement of oncolytic properties of recombinant Newcastle Disease Virus through antagonism of cellular innate immune responses. Mol Ther, 17, 697-706. https://doi.org/10.1038/mt.2008.286
- Zamarin D, Vigil A, Kelly K, et al (2009). Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther, 16, 796-804. https://doi.org/10.1038/gt.2009.14
- Zhao H, Peeters BP (2003). H. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol, 84, 781-88. https://doi.org/10.1099/vir.0.18884-0
피인용 문헌
- Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice vol.34, pp.1, 2015, https://doi.org/10.1186/s13046-015-0271-1
- Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma vol.96, pp.7, 2015, https://doi.org/10.1099/vir.0.000098
- Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect vol.11, pp.10, 2016, https://doi.org/10.1371/journal.pone.0164723
- Cytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector vol.44, pp.4, 2017, https://doi.org/10.1007/s11033-017-4113-4
- Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! vol.4, pp.3, 2016, https://doi.org/10.3390/biomedicines4030016